Davis, JM, Leucht, S, Glick, ID. CATIE findings revisited. Psychiatr Serv
2009; 60: 125–6.
Carpenter, WT, Buchanan, RW. Lessons to take home from CATIE. Psychiatr Serv
2008; 59: 523–5.
Tungaraza, T, Poole, R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry
2007; 191: 82–3.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 3: 31–41.
Swartz, MS, Stroup, TS, McEvoy, JP, Davis, SM, Rosenheck, RA, Keefe, RS, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv
2008; 59: 500–6.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUTLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Levine, SZ, Rabinowitz, J, Engel, R, Etschel, E, Leucht, S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res
2008; 98: 318–22.
Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, R. What does the PANSS mean?
2005; 79: 231–8.
Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry
2005; 187: 366–71.
Davis, JM, Chen, N, Glick, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry
2003; 60: 553–64.
Jäger, M, Riedel, M, Obermeier, M, Schennach-Wolff, R, Seemüller, F, Messer, T, et al. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. Schizophr Res
2010; 118: 183–8.
Eack, SM, Newhill, CE, Anderson, CM, Rotondi, AJ. Quality of life for persons living with schizophrenia: more than just symptoms. Psychiatr Rehabil J
2007; 30: 219–22.
Kinon, BJ, Chen, L, Asher-Svanum, H, Stauffer, VL, Kollack-Walker, S, Sniadecki, JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res
2008; 102: 230–40.
Leucht, S, Davis, JM, Engel, RR, Kissling, W, Kane, JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl
2009; 438: 7–14.
van Os, J, Burns, T, Cavallaro, R, Leucht, S, Peuskens, J, Helldin, L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand
2006; 113: 91–5.
Andreasen, NC, Carpenter, WT Jr, Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry
2005; 162: 441–9.
Opler, MG, Yang, LH, Caleo, S, Alberti, P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry
2007; 7: 35.
Leucht, S, Kissling, W, Davis, JM. The PANSS should be rescaled. Schizophr Bull
2010; 36: 461–2.